Scotland Okays First ILAP Drugs For Reimbursement
The Scottish Medicines Consortium has recommended Gilead’s Trodelvy, Amgen’s Lumykras and Pfizer’s Lorviqua for use on the Scottish National Health Service.
You may also be interested in...
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.
Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
UK Should Look To France To Speed Up Access To Innovative Medicines
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.